Provided by Tiger Trade Technology Pte. Ltd.

iShares Biotechnology ETF

200.48
-2.8600-1.41%
Post-market: 200.480.00000.00%19:30 EDT
Volume:3.62M
Turnover:722.02M
Market Cap:10.30B
PE:31.76
High:201.72
Open:200.90
Low:196.87
Close:203.34
52wk High:217.12
52wk Low:149.09
Shares:51.40M
Float Shares:51.40M
Volume Ratio:1.98
T/O Rate:7.03%
Dividend:0.35
Dividend Rate:0.17%
EPS(TTM):6.31
EPS(LYR):35.34
ROE:24.54%
ROA:0.10%
PB:1.27
PE(LYR):5.67

Loading ...

Sanofi CEO Says Expects the Market for Atopic Dermatitis Treatments to Nearly Double over the Next Five Years -Conf Call

THOMSON REUTERS
·
Oct 01

Vertex appoints Saha to Board of Directors

TIPRANKS
·
Oct 01

Press Release: Vertex Appoints DataRobot CEO Debanjan Saha to Board of Directors

Dow Jones
·
Oct 01

Regeneron Pharmaceuticals, Inc. : Argus Research Raises to Buy from Hold

THOMSON REUTERS
·
Oct 01

Stocks to Watch: Micron, Alphabet, Sanofi, Nu Holdings

Dow Jones
·
Oct 01

Sanofi’s Regeneron Fix Requires Extra Shot of M&A

Reuters
·
Oct 01

Sanofi CEO Takes First Step Toward Addressing Long-Term Outlook

Dow Jones
·
Oct 01

Sanofi to Get Pipeline Boost from Expanded Regeneron Alliance

Dow Jones
·
Oct 01

Sanofi, Regeneron Expand Tie-up with $8 Billion Drug-Development Deal, Settle Legal Dispute

Reuters
·
Oct 01

Regeneron, Sanofi Expand Antibody Alliance with USD 1 Billion Upfront Payment

Reuters
·
Oct 01

Sanofi, Regeneron Expand Antibody Alliance in Long-Acting Immunology Programs for USD 1 Billion Upfront

Reuters
·
Oct 01

Sanofi - Companies to Equally Share Development and Commercialization Costs, as Well as Any Future Profits

THOMSON REUTERS
·
Oct 01

Sanofi - and Regeneron Settle Prior Collaboration-Related Litigation

THOMSON REUTERS
·
Oct 01

Sanofi - Regeneron May Include Sanofi's Lunsekimig Therapy After Phase 3 Studies

THOMSON REUTERS
·
Oct 01

Sanofi - Regeneron to Receive $1 Bln Upfront with Potential for up to an Additional $7 Bln in Future Milestone Payments

THOMSON REUTERS
·
Oct 01

Arovella Nears First Patient Dosing in Pivotal ALA-101 Cell Therapy Trial

TIPRANKS
·
Oct 01

The Next Frontier for Obesity Drugs Isn't How Much Weight You Lose, but What Kind

Dow Jones
·
Oct 01

Regeneron Drug Halves Muscle Loss in Combination with Novo's Semaglutide in Trial

Reuters
·
Oct 01

Gilead Sciences Inc. Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Oct 01

Moderna Inc. Stock Sheds 5.4%, Underperforms Peers

Dow Jones
·
Oct 01